GlaxoSmithKline PLC has received an official license from the European Commission for Prepandrix, the first prepandemic avian flu vaccine. Several governments, including the U.S., Switzerland and Finland, have already placed orders for the vaccine, and more are expected to follow as concerns grow about "the real medical and economic threat of a pandemic," a spokesman for GSK said.

Related Summaries